AUTHORS
Annika Lintvedt-Miller, MD, Tara Alin, ANP-BC2, Ada Chang, BSc3, Kimberly A. Kasow, MD4, Paul Armistead, MD, PhD5, Jane A Little, MD6, Samuel Robert Wilson, MD, MSCR7
AFFILIATIONS
1 Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
2 Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
3 University of North Carolina at Chapel Hill School of Medicine, Blood Research Center, Chapel Hill, North Carolina, United States
4 Department of Pediatrics, Division of Pediatric Hematology, and Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
5 Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States, University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
6 Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States, University of North Carolina at Chapel Hill School of Medicine, Blood Research Center, Chapel Hill, North Carolina, United States
7 Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States, University of North Carolina at Chapel Hill School of Medicine, Blood Research Center, Chapel Hill, North Carolina, United States
ABSTRACT
Three FDA-approved autologous gene therapies (GTs) are available for eligible individuals with sickle cell disease (SCD) or beta-thalassemia (BT). These therapies, primarily studied in young adults in clinical trials, require intensive evaluation and preparation prior to actualization; older individuals and those with end-organ comorbidities are at higher risk from the acute and chronic sequelae of myeloablative chemotherapy. The Adult Transformative Care Clinic (TCC) at the University of North Carolina (UNC) was developed between the sickle cell and bone marrow transplant and cellular therapy (BMTCT) programs to medically evaluate and offer counselling to any individual who expresses interest in GT. After a multi-disciplinary review, individuals are deferred, held for optimization, or referred to BMTCT clinic for GT. The aim of our study was to characterize individuals in each stage of the process and to evaluate barriers that may be interfering with GT referral.
This was a cross-sectional study approved by the institutional review board. We characterized adult patients who had been referred to the TCC and examined clinical and logistical barriers encountered during the evaluation. Adults ³ 18 years old with SCD or BT who had been scheduled for a TCC visit at UNC from June 2024 – June 2026 were assessed. Data from electronic health records were extracted using a standardized data collection form, comprising demographics, hemoglobinopathy type, primary payer, clinical and laboratory data. Descriptive analyses were used to compare individuals who had been referred to TCC but not seen, seen in the TCC but not yet referred to BMTCT clinic, and those referred to the BMTCT clinic.
Fifty-one people were referred to the TCC, of whom 35 (69%) completed a TCC visit. Of those seen in TCC, the median (range) age was 34 (20-55) years and 66% were male, compared to 45% in the overall clinic. Most had HbSS disease (79%), and among those, median hemoglobin was 9.6 g/dL, reticulocytes 205 109/L, and LDH 366 U/L (ULN 250). For primary payer (TCC vs general clinic population), private insurance was the most common (49% vs 29%), followed by Medicaid (22% vs 32%), and Medicare (20% vs 28%). Eighty-two percent had a daily morphine milligram equivalent (MME) of < 30, with median (interquartile range) emergency department visits and hospitalizations of 0.5 (0-3) and 1 (0-2), respectively. Following evaluation in the TCC, 29% were referred to BMTCT, 23% required optimization, 26% were deemed ineligible, and 23% declined GT at that time. Reasons for optimization included the need for subspecialty clearance, completion of recommended pre-referral screening (e.g. MRI/MRA, fibroscan), or need to taper opioids. Medical comorbidities, age > 50, inability to transfuse (n=2), untested SCD types (n=3) and adherence were among reasons for ineligibility. Reasons for declining GT varied but included life circumstances such as schooling, desire for near pregnancy, time burden, and further contemplation after education. Of those ultimately referred to BMTCT, 80% had HbSS. Time from BMTCT visit to insurance approval has improved from a maximum of >1 year to a minimum of approximately two weeks.
We found that only 29% of people who expressed interested in GT were ultimately referred to BMTCT. Approximately half of our TCC referred population required optimization and/or continued follow-up to assess evolution of interest. Notable disparities in GT access included gender, with males disproportionately represented, possibly reflecting concerns regarding future fertility, and insurance payer, with Medicaid and Medicare underrepresented, which may reflect factors related to overall socioeconomic status. This data highlights areas for improving GT access, including proactive management of comorbidities, more support for financial and logistical barriers, and addressing gender disparities. Ongoing education and community involvement, along with refocused efforts to improve access to GT are essential to ensure adequate delivery of transformative therapies in the next decade.
DISCLOSURES
Annika Lintvedt-Miller, MD: No relevant conflicts of interest to declare.